GI Oncology Now

Gulam Abbas Manji, MD, PhD, of Columbia University Irving Medical Center, discusses the ARC-8 study, which analyzed the efficacy of the novel CD73 inhibitor quemliclustat when used in combination with gemcitabine/nab-paclitaxel with and without zimberelimab.

Dr. Manji elaborates on the rationale behind targeting CD73 inhibition with standard-of-care chemotherapy and anti-PD-1 therapy, and describes the initial efficacy results of the study.

In this special episode of Healthcare Unfiltered, Dr. Tanios Bekaii-Saab, of the Mayo Clinic, joins Dr. Chadi Nabhan to discuss the most groundbreaking studies unveiled at the 2024 ASCO GI Symposium, including an examination of the crucial, previously reported data from IMbrave050 and EMERALD-1.